Physician profile
Mark L Phillips
NPI 1275511966
$4,982.38
in general payments reported to CMS, 2019-2025
38 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $446 · 2021: $985 · 2022: $866 · 2023: $650 · 2024: $336 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $820.06 | 2019-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $626.75 | 2019-2025 | Relistor |
| Lundbeck LLC | $533.39 | 2021-2025 | Vyepti |
| Pfizer INC. | $388.99 | 2019-2025 | |
| Boston Scientific Corporation | $330.91 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Redhill Biopharma INC. | $274.28 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $205.88 | 2019-2022 | |
| Assertio Therapeutics, INC. | $197.30 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $175.14 | 2019-2021 | |
| Amgen INC. | $161.06 | 2021-2022 | |
| Abbvie INC. | $135.59 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $124.03 | 2025 | |
| Ibsa Pharma INC. | $104.07 | 2020-2021 | |
| Daiichi Sankyo INC. | $91.03 | 2019 | |
| Nevro Corp. | $76.37 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.